Xiaolin Zhang, Dizal CEO

#ES­MO22: Dizal touts win in niche NSCLC pop­u­la­tion cor­nered by Take­da, J&J

As­traZeneca spin­out Dizal said its can­cer drug cleared the pri­ma­ry goal in a Phase II tri­al of pa­tients with EGFR ex­on 20 in­ser­tion mu­ta­tions, for …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.